The debut of troglitazone, a potent glucose-lowering agent, marked a significant chapter in the control of type 2 diabetes. However, its removal from the market due to severe hepatotoxicity spurred considerable investigation into related thiazolidinediones. Following pioglitazone and rosiglitazone emerged, offering similar mechanisms of action –